RxDoctor Payments Data

Paul Sidoti, MD

Ophthalmology · New York, NYNPI 1871600510

Payments from drug & device makers

$2,783in general payments, 2019–2025

Across 22 payments — averaging $126.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$750
  • Alcon$589
  • AbbVie$580
  • Glaukos Corporation$204
  • Carl Zeiss Meditec Cataract Technology Inc.$192
  • NEW World Medical,inc.$164
  • plus $305 from 3 others

What the payments were for

  • Speaking & faculty fees$75027%
  • Food & beverage$1,95370%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,783 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$97,302
Medicare patients
212
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost86$53,920
Alphagan PBrimonidine Tartrate115$48,323
LumiganBimatoprost115$45,177
RhopressaNetarsudil Mesylate29$18,989
VyzultaLatanoprostene Bunod38$12,219
ProlensaBromfenac Sodium17$10,632
Cosopt PfDorzolamide/Timolol/Pf50$9,316
Brimonidine Tartrate60$8,563
Brinzolamide44$8,308
Prednisolone Acetate129$6,490
CombiganBrimonidine Tartrate/Timolol17$6,244
ZioptanTafluprost/Pf17$6,018
Dorzolamide-TimololDorzolamide/Timolol/Pf24$5,092
Difluprednate32$4,766
Bromfenac Sodium22$4,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Lumigan, Combigan$580$99,745247 claims
Bausch & Lomb Americas Inc.Vyzulta$750$12,21938 claims
AlconSimbrinza$589$4,10119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →